Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome

Novo Nordisk A/S2,016 enrolled

Overview

This study is conducted in Japan. The aim of this study is to collect information about the efficacy and safety of Norditropin® (somatropin) in the long-term treatment of short stature with GHD (Growth Hormone Deficiency) where epiphysial discs are not closed and short stature with Turner Syndrome where epiphysial discs are not closed.

Study Type

OBSERVATIONAL

Enrollment

2,016

Conditions

Growth Hormone Disorder Growth Hormone Deficiency in Children Genetic Disorder Turner Syndrome

Interventions

somatropinDRUG

Collection of safety and efficacy data in connection with use of somatropin (Norditropin®) in daily clinical practice.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Growth hormone deficiency or short stature due to Turner Syndrome where the epiphyseal discs are not closed Exclusion Criteria: * Diabetic * Patients with malignant tumors * Women who are either pregnant or likely to be pregnant * Known or suspected allergy to study product(s) or related products

Locations (1)

Unnamed facility

Tokyo, Japan

Outcomes

Primary Outcomes

Change from baseline in height

Time frame: Week 0, Month 36, final height is reached

Incidence of adverse reactions (ADRs)

Time frame: 36 months, accumulation of study period

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.